

Commissioner is hereby authorized to charge any additional fees under to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Please amend the application as follows.

IN THE SPECIFICATION

Please enter into the application the Substitute Sequence Listing submitted herewith.

Please enter the Replacement Sheets of Figures 14(A-J) and 19(A-N) submitted herewith.

Remarks

Sequence Listing Matters

In response to the Notice to Comply, Applicants submit herewith a substitute Sequence Listing on CD-ROM and paper copy. A copy of the Notice to Comply is also included. No new matter is added by way of the substitute sequence listing. The substitute listing differs from the previously filed sequence listing in that the substitute listing includes additional sequences (SEQ ID NOS.: 28 and 29) corresponding to the complement sequences provided in Figures 14 (A-J) and 19 (A-N). SEQ ID. NO.: 28 corresponds to the complement of SEQ ID. NO.: 10, and SEQ ID NO.: 29 corresponds to the complement of SEQ. ID. NO: 23. The sequence information corresponding to SEQ ID NOS.: 28 and 29 was set forth in Figures 14 and 19, respectively, in the application as filed.

Entry of the substitute sequence listing is respectfully requested.